瑞康醫藥(002589.SZ):上半年淨利降45.10%至2.10億元
格隆匯8月27日丨瑞康醫藥(002589.SZ)披露2020年半年度報告,報告期內,公司實現總收入126.87億元,同比下降29.35%;歸屬於上市公司股東的淨利潤2.10億元,同比下降45.10%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.22億元,同比下降67.24%。
公司業務與醫療機構的需求密切相關,疫情前期由於下游醫療機構限制流量,常見病、慢性病患者數量大量減少,大量患者的就醫需求被抑制,對公司業務造成了一定影響;隨着疫情防控組織得當,措施有力,國內疫情形勢趨於緩和,醫療機構逐步恢復正常運行,公司業務逐步恢復。報告期內,受新冠疫情影響,公司業務與上年同期相比,發展速度有所下降。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.